These data show that cynomolgus macaques are permis-sive to SARS-CoV-2 infection, shed virus for a prolonged pe-riod of time and display COVID-19-like disease. In this non-human primate model, SARS-CoV-2 replicates efficiently in respiratory epithelial cells throughout the respiratory tract, including nasal cavity, bronchi, bronchioles, and alveoli. Rep-lication in the upper respiratory tract fits with efficient trans-mission between hosts, while replication in the lower respiratory tract fits with the development of lung disease. An in-depth comparison of infection with SARS-CoV, MERS-CoV and SARS-CoV-2 in this model may identify key path-ways in the pathogenesis of these emerging viruses. This study provides a novel infection model which will be critical in the evaluation and licensure of preventive and therapeutic strategies against SARS-CoV-2 infection for use in humans, as well as evaluating the efficacy of repurposing species specific existing treatments, such as pegylated interferon (12).
These data show that cynomolgus macaques are permis-sive to SARS-CoV-2 infection, shed virus for a prolonged pe-riod of time and display COVID-19-like disease. In this non-human primate model, SARS-CoV-2 replicates efficiently in respiratory epithelial cells throughout the respiratory tract, including nasal cavity, bronchi, bronchioles, and alveoli. Rep-lication in the upper respiratory tract fits with efficient trans-mission between hosts, while replication in the lower respiratory tract fits with the development of lung disease. An in-depth comparison of infection with SARS-CoV, MERS-CoV and SARS-CoV-2 in this model may identify key path-ways in the pathogenesis of these emerging viruses. This study provides a novel infection model which will be critical in the evaluation and licensure of preventive and therapeutic strategies against SARS-CoV-2 infection for use in humans, as well as evaluating the efficacy of repurposing species specific existing treatments, such as pegylated interferon (12).
正在翻译中..